SCHEMBL28008353

SCHEMBL28008353

Cc1ccccc1Cn1ccc(C(N)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 3/20 0.43
ALDH1A1 P00352 3/20 0.43
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
KCNH2 Q12809 1/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
AKR1B1 P15121 1/20 0.41
KLKB1 P03952 1/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7184029 0.80 ERCC5 (0.49) CYP11B1CYP11B2LMNAHTTSMN1; SMN2
SCHEMBL4155873 0.79 CYP2C19 (0.53) OPRK1AKR1B1KLKB1POLBCA2
SCHEMBL28275207 0.76 NAMPT (0.46) CYP11B1CYP11B2LMNAHTTSMN1; SMN2
SCHEMBL20481563 0.75 ALDH1A1 (0.51) LMNASMN1; SMN2HPGDALDH1A1OPRM1
SCHEMBL9714504 0.75 CYP11B1 (0.47) CYP11B1CYP11B2SMN1; SMN2PTGS1PTGS2
SCHEMBL4553409 0.74 AKR1B1 (0.41) MEN1KMT2AAKR1B1POLBCA2
SCHEMBL3819996 0.74 AKR1B1 (0.43) ALDH1A1KMT2AAKR1B1POLBCA2
SCHEMBL28274090 0.72 CTRB1 (0.51) MEN1KMT2AKLKB1CA2
SCHEMBL27383724 0.72 CYP11B1 (0.61) CYP11B1CYP11B2LMNAHTTSMN1; SMN2
SCHEMBL3429972 0.71 PLAU (0.44) CYP11B1CYP11B2LMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103080104-B N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein NOVARTIS AG 2015-04-08 CN disclosed